Disease
Pancreatic cancer胰腺癌
ICD-10: C25 — Malignant neoplasm of pancreas
Key figures
Published values only. Every tile opens the section that carries its source, its year and its caliber.
Disease details
- Standard Chinese name
- 胰腺癌
- English name
- Malignant neoplasm of pancreas
Values written in Chinese are quoted as published by the source.
Also known as
- Pancreatic carcinoma
- Pancreatic ductal adenocarcinoma
Treatment cost ranges
Every range below is published on one billing basis: Pre-reimbursement 医保报销前. The sources publish no post-reimbursement figure, so none is shown here.
| Treatment path | Cost range | Price basis | Data year |
|---|---|---|---|
| Surgery 手术 | 90000 – 90000 CNY | Condition package price 病种打包全包价 | 2020 |
| Surgery 手术 | 85000 – 85000 CNY | Condition package price 病种打包全包价 | 2020 |
The bars share one scale across the rows above: each starts at that row's lower published figure and ends at its upper one. The highest upper figure on this page is 90000 CNY. Each row keeps its own data year and caliber.
2 cost ranges for this condition, each with its source on the row page.
Values written in Chinese are quoted as published by the source.
Five-year survival
5-year survival rate 8.5%
- Population
- Overall (all stages combined) · Age-standardised relative survival 总体(全分期合并)· 年龄标准化相对生存率
- Period
- 2019–2021
- Publisher
- National Cancer Center 国家癌症中心
- Value nature
- Estimated value (hybrid analysis) 估计值(混合法)
- Registry scope
- 281 population-based cancer registries 281 个肿瘤登记处
- Stage data availability
- Not published
Values written in Chinese are quoted as published by the source.
How to read this figure. It is published for all stages combined, so it is an average over everyone in the national registry data rather than a prognosis for one person. For most cancers, the stage at diagnosis is the strongest single factor behind survival differences: survival is generally higher when the cancer is found at an earlier stage and lower when it is found later. Comparisons between cancers are also shaped by how early or late each one tends to be diagnosed, so a lower figure does not by itself mean worse care.
Hospitals with a published record for this condition
Selected using official public data sources
These hospitals are selected from official public data sources — the Fudan University hospital specialty reputation rankings, the national key clinical specialties list and national clinical research centres — so each line on a card can be checked against its published source. This is not a paid or promoted listing.
How these hospitals were selected
Admission. A hospital is listed for a condition when the specialty that condition is filed under carries at least one of: a place or a nomination in the Fudan University hospital specialty reputation ranking; a national key clinical specialty record at level A, B or C; or a national clinical research centre or a state key laboratory in that specialty. JCI accreditation is shown as a badge; it never decides admission and it never decides order.
Order. Step 1: a Fudan place between 1 and 10 for the specialty. Step 2: another Fudan place, or a nomination. Step 3: a level-A national key clinical specialty. Step 4: a level-B national key clinical specialty. Step 5: a national clinical research centre or a state key laboratory in the specialty, a centre before a laboratory. Step 6: a level-C national key clinical specialty, which is a record we publish without an independent official source and which is therefore listed after the others.
Ties. Within one step: the better Fudan place first, then the stronger key-specialty level (A before B before C), then the province, then the city, then the hospital name - the same province-city-name order the hospital directory uses. At most eight hospitals are listed.
When the list is short. Five hospitals or more: the first eight are listed. Three or four: all of them are listed, and a further fold adds the remaining records up to eight, each carrying its evidence level. One or two: the same, with that fold open and a line stating how many hospitals have a strong public record. None: the page states that no strong public record was found and links to the specialty directory. A place, an institution or a count is never invented to fill the list.
The Fudan rankings are the hospital specialty reputation ranking most widely recognised by Chinese clinicians, published annually by Fudan University's hospital management institute.
-
Cancer Hospital of Chinese Academy of Medical Sciences中国医学科学院肿瘤医院
Fudan specialty reputation ranking 2023
- Medical Oncology #1 https://www.fdygs.com/news2023-1.aspx
National key clinical specialty
- Medical Oncology (level B) https://www.cicams.ac.cn/news/401.html
Research platform
- 国家恶性肿瘤临床医学研究中心 https://www.most.gov.cn/tztg/201306/t20130608_106459.html
Also ranked: Thoracic Surgery #1, Urology nominated in the Fudan list.
-
Peking Union Medical College Hospital中国医学科学院北京协和医院
Fudan specialty reputation ranking 2023
- General Surgery #1 https://www.fdygs.com/news2023-1.aspx
- Medical Oncology nominated https://www.fdygs.com/news2023-1.aspx
Also ranked: Urology #8, Gynecology #1, Otorhinolaryngology #4 in the Fudan list.
-
Zhongshan Hospital复旦大学附属中山医院
Fudan specialty reputation ranking 2023
- General Surgery #2 https://www.fdygs.com/news2023-1.aspx
- Medical Oncology nominated https://www.fdygs.com/news2023-1.aspx
National key clinical specialty
- General Surgery (level B) https://www.zs-hospital.sh.cn/zhuanye/content/5140.html
Also ranked: Thoracic Surgery #6, Gastroenterology #9, Respiratory Medicine #6 in the Fudan list.
-
Sun Yat-sen University Cancer Center中山大学肿瘤防治中心
Fudan specialty reputation ranking 2023
- Medical Oncology #2 https://www.fdygs.com/news2023-1.aspx
National key clinical specialty
- General Surgery (level B) https://www.sysucc.org.cn/node/8565
- Medical Oncology (level B) https://www.sysucc.org.cn/node/8565
Also ranked: Thoracic Surgery #9 in the Fudan list.
-
West China Hospital, Sichuan University四川大学华西医院
Fudan specialty reputation ranking 2023
- General Surgery #3 https://www.fdygs.com/news2023-1.aspx
- Medical Oncology #8 https://www.fdygs.com/news2023-1.aspx
National key clinical specialty
- General Surgery (level A) https://wcums.scu.edu.cn/kxyan_jiu/gjlczdzk.htm
- Medical Oncology (level A) https://wcums.scu.edu.cn/kxyan_jiu/gjlczdzk.htm
Also ranked: Thoracic Surgery #4, Urology #2 (tied), Otorhinolaryngology #8 in the Fudan list.
-
Fudan University Shanghai Cancer Center复旦大学附属肿瘤医院
Fudan specialty reputation ranking 2023
- Medical Oncology #3 https://www.fdygs.com/news2023-1.aspx
National key clinical specialty
- Medical Oncology (level B) https://www.shca.org.cn/home/news/content/id/297/pid/25651
- Hepatobiliary Surgery (level B) https://www.shca.org.cn/home/news/content/id/297/pid/25651
Also ranked: Thoracic Surgery #10, Nuclear Medicine 核医学 nominated in the Fudan list.
-
Ruijin Hospital上海交通大学医学院附属瑞金医院
Fudan specialty reputation ranking 2023
- General Surgery #4 https://www.fdygs.com/news2023-1.aspx
National key clinical specialty
- General Surgery (level B) https://www.rjh.com.cn/2018RJPortal/lcyxy2019/sy/jj/index.shtml
- Medical Oncology (level B) https://www.rjh.com.cn/2018rjportal/rjzlk/ksjs/index.shtml
Also ranked: Thoracic Surgery #7 (tied), Respiratory Medicine #5, Infectious Diseases 传染感染 #6 in the Fudan list.
-
Peking University Cancer Hospital北京大学肿瘤医院
Fudan specialty reputation ranking 2023
- Medical Oncology #4 https://www.fdygs.com/news2023-1.aspx
National key clinical specialty
- Medical Oncology (level B) https://www.bjcancer.org/Html/Hospitals/Main/Description.html
Also ranked: Nuclear Medicine 核医学 nominated in the Fudan list.
Clinical trials (investigational treatments)
In addition to standard care, clinical research studies for Pancreatic cancer may currently be open to participants in China. The treatments under study have not been approved by the regulator as standard therapy — they are clinical research, not routine treatment. Each record names the lead investigator and the hospital running the study. If you are interested, contact the hospital to ask about eligibility and choose whether to apply.
-
Study Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pancreatic Cancer With Risk Factors:A Prospective Exploratory Study
- Hospital
- Ningbo Medical Center Lihuili Hospital
- Status
- Recruiting
- Registry
- NCT07542002
-
Study Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients
- Hospital
- Ningbo Medical Center Lihuili Hospital
- Status
- Recruiting
- Registry
- NCT06375473
-
Study A Multicenter Study Assessing the Efficacy and Safety of Icaritin in Combination With AG Chemotherapy Versus AG Chemotherapy Alone in Patients With Previously Untreated Advanced Pancreatic Ductal Adenocarcinoma
- Hospital
- Sun Yat-sen Memorial Hospital, Sun Yat-sen University
- Status
- Recruiting
- Registry
- NCT06825546
-
Study An Open-label, Single-center, Single-arm Study to Evaluate the Efficacy and Safety of Low-dose Radiation Therapy Combined With Pultelimab and Standard Treatment in Patients With Advanced Pancreatic Cancer
- Lead investigator
- Liu Yang · MD
- Hospital
- Zhejiang Provincial People's Hospital
- Status
- Recruiting
- Registry
- NCT07312422
-
Study A Phase II Trial to Evaluate the Efficacy of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Patients With Advanced Pancreatic Tumors
- Hospital
- Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University
- Status
- Recruiting
- Registry
- NCT07006077
21 more registered studies
-
Study A Phase 1/2, Open-label, Biomarker-guided, Dose-escalation and Expansion Study of Dual-targeting CAR-NK Cells Directed Against Mesothelin (MSLN) and MUC1, With an Exploratory CLDN18.2/MUC1 Dual-target Cohort, in Patients With Unresectable or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
- Hospital
- Peking University Shenzhen Hospital
- Status
- Recruiting
- Registry
- NCT07627711
-
Study A Multicenter, Randomized, Open-label, Active-controlled, Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine Versus Nab-paclitaxel Plus Gemcitabine as the First-line Treatment in Metastatic Pancreatic Cancer
- Hospital
- Anhui Provincial Hospital
- Status
- Recruiting
- Registry
- NCT06361888
-
Study Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cancer Liver Metastasis Efficacy and Safety
- Lead investigator
- Jiang Long · Chief physician of hepatobiliary and pancreatic surgery
- Hospital
- Shanghai General Hospital
- Status
- Recruiting
- Registry
- NCT06531278
-
Study A Proof of Concept Study of Pancreatic Cancer Early Detection by cfDNA Assay
- Lead investigator
- Xian-Jun Yu · Principal Investigator
- Hospital
- Fudan University Shanghai Cancer Center
- Status
- Recruiting
- Registry
- NCT06166147
-
Study Clinical Study of Multimodal Ablation Remodeling Immunosensitized PD-1 in the Treatment of Pancreatic Cancer With Liver Metastasis
- Lead investigator
- Jiang Long · Chief physician of hepatobiliary and pancreatic surgery
- Hospital
- Shanghai General Hospital
- Status
- Recruiting
- Registry
- NCT06307080
-
Study Profiling the Intratumoral Microbiome of Pancreatic Ductal Adenocarcinoma Based on EUS-FNB Tissue Samples and Exploring Its Impact on Tumor Diagnosis and Prognosis.
- Lead investigator
- Li Tian, MD · Li Tian, MD [fu3tianli]
- Hospital
- Xiangya Hospital of Central South University
- Status
- Recruiting
- Registry
- NCT06655233
-
Study A Single-arm, Exploratory Clinical Study of Trilaciclib Combined With mFOLFIRINOX Regimen in the Treatment of Patients With Advanced Pancreatic Cancer
- Hospital
- Nanjing Drum Tower Hospital
- Status
- Recruiting
- Registry
- NCT06151262
-
Study Clinical Trial Evaluating the Safety and Activity of Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer
- Lead investigator
- Guo ShiWei
- Status
- Recruiting
- Registry
- NCT04146298
-
Study A Randomized, Double-blind, Parallel-controlled, Multicenter Phase III Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules to Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
- Hospital
- First Affiliated Hospital of Guangzhou Medical University
- Status
- Recruiting
- Registry
- NCT07165951
-
Study A Study on a Predictive Model for Efficacy and Prognosis of Pancreatic Carcinoma Based on Multimodal Data
- Hospital
- Zhongshan Hospital
- Status
- Recruiting
- Registry
- NCT07561814
-
Study An Exploratory Clinical Study of HRS-4642 in Combination With Immunotherapy and Chemotherapy for Pancreatic Cancer
- Hospital
- Zhongshan Hospital
- Status
- Recruiting
- Registry
- NCT06938282
-
Study An Exploratory Clinical Study of HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
- Lead investigator
- BAIYONG SHEN · Professor
- Hospital
- Ruijin Hospital
- Status
- Recruiting
- Registry
- NCT06587061
-
Study Clinical Study of Personalized Tumor Vaccines mRNA-0217/S001 and Pabolizumab in Patients With Advanced Pancreatic Cancer
- Hospital
- Ruijin Hospital
- Status
- Recruiting
- Registry
- NCT05916261
-
Study Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer: a Prospective, Randomized Controlled Clinical Trial
- Lead investigator
- Dai, Guanghai · Professor
- Hospital
- Chinese PLA General Hospital
- Status
- Recruiting
- Registry
- NCT05218889
-
Study A Study to Evaluate the Human Biodistribution and Dosimetry of the Radionuclide Labeled IR199 in Patients With Gastric Cancer and Pancreatic Cancer
- Lead investigator
- YiHui Guan · Professor
- Hospital
- Huashan Hospital
- Status
- Recruiting
- Registry
- NCT07707531
-
Study Human Chimeric Antigen Receptor Macrophages Targeting C-MET for C-MET-positive Advanced Stage of Pancreatic Cancer Patients: A Single-arm, Single-center, IIT Study
- Hospital
- Peking Union Medical College Hospital
- Status
- Not yet recruiting
- Registry
- NCT07553793
-
Study Efficacy and Safety of XH001 (New Antigen Tumor Vaccine) Combined With Chemotherapy as Adjuvant Therapy in Pancreatic Cancer Patients
- Hospital
- Peking Union Medical College Hospital
- Status
- Not yet recruiting
- Registry
- NCT07114666
-
Study Efficacy and Safety of Serplulimab in Combination With Bevacizumab and FOLFIRINOX or NALIRIFOX as Second-Line Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: An Open-Label, Single-Arm, Phase II Study
- Lead investigator
- Fan Wang · Associate Chief Physician
- Hospital
- Shanghai General Hospital
- Status
- Not yet recruiting
- Registry
- NCT07733050
-
Study A Clinical Study Evaluating the Safety, Tolerability, Preliminary Efficacy and Immunogenicity of a Tumor Vaccine Injection Targeting Stressinducible Proteins MICA/B in Combination With the AG Regimen in Patients With Metastatic Pancreatic Cancer
- Hospital
- Xiangya Hospital of Central South University
- Status
- Not yet recruiting
- Registry
- NCT07231094
-
Study Immune Repertoire Decoding Enables Dynamic Risk Stratification During Chronic Pancreatitis-to-Pancreatic Cancer Transition
- Lead investigator
- Zhuan Liao
- Status
- Not yet recruiting
- Registry
- NCT07762950
-
Study The Efficacy and Safety of Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer: A Prospective, Single Arm, Phase II Clinical Study
- Hospital
- Zhongshan Hospital
- Status
- Not yet recruiting
- Registry
- NCT06166589
This page only shares publicly registered study information. It does not recommend or encourage joining any study. Participation is entirely voluntary and the risks of an unapproved treatment are unknown; contact the hospital directly for eligibility and informed-consent details.
Hospitals with a national key specialty record
Show the hospital records 66 hospitals with a key-specialty record
Each row is a hospital with a national key clinical specialty record in a specialty this condition is filed under. This is a record of published listings, not a recommendation and not a ranking.
66 hospitals with a matching national key specialty record.
Values written in Chinese are quoted as published by the source.
Questions about this condition
We cannot give medical advice, but we can answer questions about this page and about arranging treatment in China.
ICD codes
Show the code table 1 ICD code
| Version | Code | Name in that version |
|---|---|---|
| ICD-10-WHO | C25 | Malignant neoplasm of pancreas |
Rows are the WHO ICD-10 entries for this condition, quoted as published.
Source & evidence
- Source URL
- https://qzybj.quanzhou.gov.cn/qt/gzcx/bzsfcx/202006/P020221216571645625406.pdf
- Source scheme
- https
- Source type
- Provincial health commission
- Evidence level
- A - said by a provincial health commission or university
- Retrieved on
- 2026-09-30